Yago Garitaonaindía, Translational Research Fellow at CCIT-DK – National Center for Cancer Immune Therapy of Denmark, shared on X:
“IOV-COM-202 1A at ESMO26: lifileucel + pembro, 1L melanoma (n=24) -Andrew Furness
ORR 62.5% | CR 29% | mPFS 19.8 mo | mDOR NR (26.9 mo FU).
My key points:
- Known toxicity limiting generalizability
- Phase 3 vs pembro mono, not ipi-nivo. This toxicity has to pay off
- IL-2-sparing, low-intensity lymphodepletion approaches (e.g. OBX-115) coming from behind
- Resection after 1st pembro dose?”
You may also find this interesting:
